Washington is currently home to 1721 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Seattle, Spokane, Tacoma and Vancouver. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery
NCT05316688
Recruiting
This phase I/II trial studies the side effects of tozuleristide in imaging oral cavity squamous cell cancer and high-grade oral cavity dysplasia during surgery. Tozuleristide is an imaging agent that specifically binds to tumor cells. When exposed to near-infrared light, tozuleristide causes tumor cells to fluoresce (light up), so that surgeons may better distinguish tumor cells from healthy cells during surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/09/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Oral Cavity Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8
Register for Updates
Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)
NCT05238116
Recruiting
To assess the safety and efficacy of nebulized PC945 in combination with systemic antifungal therapy for the treatment of refractory IPA
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/09/2025
Locations: Clinical Research Site 026, Seattle, Washington
Conditions: Refractory IPA
Register for Updates
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
NCT04419519
Recruiting
This study will find out whether people with CLL or SLL who have received treatment with venetoclax, either alone or in combination with another drug, and who are found to be MRD-negative, can stop treatment with venetoclax and remain off-treatment for 12 months or more. The researchers will also see whether study participants remain MRD-negative after they stop treatment with venetoclax.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/09/2025
Locations: University of Washington, Seattle, Washington
Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Register for Updates
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
NCT04378790
Recruiting
A randomized trial to determine whether simultaneous treatment with spectacles and patching has an equivalent VA outcome compared with sequential treatment, first with spectacles alone followed by patching (if needed), for previously untreated amblyopia in children 3 to \<13 years of age.
Gender:
ALL
Ages:
Between 3 years and 13 years
Trial Updated:
06/09/2025
Locations: Seattle Children's Hospital, University of Washington, Seattle, Washington
Conditions: Amblyopia
Register for Updates
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
NCT04375033
Recruiting
VA-BRAVE will determine whether a 28-day long-acting injectable sub-cutaneous (in the belly area) formulation of buprenorphine at a target dose of 300mg is superior in retaining Veterans in opioid treatment and in sustaining opioid abstinence compared to the daily sublingual (under the tongue) buprenorphine formulation at a target dose of 16-32 mg (standard of care). This is an open-label, randomized, controlled trial including 952 Veterans with opioid use disorder (OUD) recruited over 7 years a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/09/2025
Locations: VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington
Conditions: Opioid Use Disorder
Register for Updates
A Study of Bleeding and Treatment in Participants With Von Willebrand Disease
NCT06610201
Recruiting
The purpose of this screening study is to accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeds in participants with Von Willebrand Disease (VWD). Data from this study will be used to establish baseline bleeding and treatment rates in a population of participants with VWD and act as comparator data for future clinical study outcomes.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
06/06/2025
Locations: Washington Institute For Coagulation (WIC), Seattle, Washington
Conditions: Von Willebrand Disease (VWD), Von Willebrand Disease, Type 3, Von Willebrand Disease, Type 2B, Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2 and Type 3
Register for Updates
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
NCT06556368
Recruiting
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/06/2025
Locations: Pacific Northwest Retina, Bellevue, Washington
Conditions: Wet Age-related Macular Degeneration
Register for Updates
PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm
NCT06445608
Recruiting
This purpose of this trial is to demonstrate 30 day safety and effectiveness outcomes of the KARDION CORY P4 System in subjects who require hemodynamic support during a high-risk PCI procedure.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
06/06/2025
Locations: University of Washington, Seattle, Washington
Conditions: Coronary Artery Disease
Register for Updates
Evaluation of A Clinical Diagnostic Test for CRDS
NCT06188689
Recruiting
Calcium Release Deficiency Syndrome (CRDS) is a novel inherited arrhythmia syndrome secondary to RyR2 loss-of-function that confers a risk of sudden cardiac death. Diagnosis of CRDS presently requires cellular-based in vitro confirmation that an RyR2 variant causes loss-of-function. We hypothesize that CRDS can be diagnosed clinically through evaluation of the repolarization response to brief tachycardia, mediated by cardiac pacing, and a subsequent pause.
Gender:
ALL
Ages:
All
Trial Updated:
06/06/2025
Locations: University of Washington, Seattle, Washington
Conditions: Calcium Release Deficiency Syndrome (CRDS)
Register for Updates
Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)
NCT06023459
Recruiting
This pilot trial will explore the feasibility, acceptability, and effectiveness of the most recently approved formulation of injectable extended-release buprenorphine (XR-BUP) for treatment of opioid use disorder (OUD) in rural settings. We will randomize 144 eligible individuals with moderate to severe OUD in a 2:1 ratio to one of two medication conditions: (1) XR-BUP (128mg target), administered every 4 weeks or (2) SL-BUP (16mg-24 mg/day target).Participants will receive study medication trea... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Providence Northeast Washington Medical Group, Colville, Washington
Conditions: Opioid-Related Disorders, Substance-Related Disorders, Narcotic-Related Disorders
Register for Updates
Fontan Udenafil Exercise Longitudinal Assessment Trial - 2
NCT05918211
Recruiting
This study will evaluate the clinical efficacy and safety of udenafil, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of adolescent who have had the Fontan procedure.
Gender:
ALL
Ages:
Between 12 years and 18 years
Trial Updated:
06/06/2025
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Single Ventricle Heart Disease
Register for Updates
Targeted Pediatric High-Grade Glioma Therapy
NCT05839379
Recruiting
The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma. This molecular profiling will decide if patients are eligible to participate in a subsequent treatment-based clinical trial based on the genetic alterations identified in their tumor.
Gender:
ALL
Ages:
Between 12 months and 39 years
Trial Updated:
06/06/2025
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma, Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Brain Tumor, WHO Grade III Glioma, WHO Grade IV Glioma
Register for Updates